0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Contributors
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          Journal
          Amyloid
          Amyloid
          Informa UK Limited
          1350-6129
          1744-2818
          April 03 2019
          May 23 2019
          April 03 2019
          : 26
          : 2
          : 74-84
          Affiliations
          [1 ] Neuromuscular Disorders Clinic, Department of Neurology, Vall d’Hebron University Hospital, VHIR, European Reference Network on Rare, Neuromuscular Disorders (ERN EURO-NMD), UAB, Barcelona, Spain;
          [2 ] Research and Development Department, SOM Biotech, S.L, Barcelona, Spain;
          [3 ] Pharmacy Department, Vall d’Hebron Research Institute (VHIR), Hospital Universitari Vall d’Hebron, Barcelona, Spain;
          [4 ] Neuromuscular Disorders Unit, Neurology Department, Bellvitge University Hospital – IDIBELL, Barcelona, Spain;
          [5 ] Department of Neurology, Neuromuscular Diseases Unit Hospital de la Santa Creu i Sant Pau, Center for Networked Biomedical Research into Rare Diseases (CIBERER), UAB, Barcelona, Spain
          Article
          10.1080/13506129.2019.1597702
          © 2019

          Comments

          Comment on this article